BEVERLY HILLS, Calif., July 29, 2014 /PRNewswire/ -- ImmunoClin Corporation (IMCL) is a U.S. healthcare company specializing in personalized medicine, treatment of infectious diseases as well as nutraceuticals. The company is developing strategies of prognosis and prevention of pathologies like cardiovascular disease, Alzheimer's disease and gastrointestinal disorders. As of August 1, 2014, ImmunoClin Corporation will complete the strategic relocation of its corporate headquarters to Washington, D.C., a key center of North American healthcare and biotechnology industries and related governmental agencies. In addition, the Company's chief operating officer, general counsel, and director, Chad S. Johnson, Esq., who will oversee the principal corporate office, is a decades-long D.C. resident.
"We are excited to move ImmunoClin's head office to Washington, D.C. The location is attractive for obvious regulatory and business reasons, as we continue to progress our strategic growth plan. Further, under the oversight of officer and director, Chad Johnson, the Washington office will work seamlessly with our established European headquarters in London, United Kingdom and laboratories in central Paris, France," said Dr. Dorothy Bray, Director, President and CEO of ImmunoClin Corporation.
"Washington, D.C. is a great location for the Company's principal office. ImmunoClin will join the ranks of the expansive tech and healthcare presence in the D.C. area and be positioned to take advantage of the proximity to and interaction with the federal government, including departments and agencies such as HHS, FDA, NIH, USPHS, and USPTO -- not to mention the impressive public and private educational and research institutions located in greater D.C.," said Chad S. Johnson, Esq., Director, COO and General Counsel. "I am honored to spearhead the efforts of IMCL from our new D.C. office in conjunction with our international board of directors and scientific advisory board."
About ImmunoClin Corporation
ImmunoClin Corporation is a healthcare company with European headquarters in London, United Kingdom and laboratories in central Paris, France -- and principal corporate office being established in Washington, D.C., USA. ImmunoClin concentrates its innovation on developing personalized and preventive strategies to fight inflammatory conditions that are the underlying cause of pathologies in multiple conditions affecting the majority of the human population: infections, cancer, cardiovascular disease, and dementia, including Alzheimer's disease. ImmunoClin holds multiple patents and trademarks on a global basis.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of technologies, pharmaceuticals, and food products. ImmunoClin Corporation does not undertake any duty nor does it intend to update the results of these forward-looking statements.
J. Scott Munro, CFO
Cell: +1 778-987-4308
|SOURCE ImmunoClin Corporation|
Copyright©2014 PR Newswire.
All rights reserved